Options Trading News

April 5, 2011  Tue 7:33 AM CT

Deal to Help Cubist Grow Business

CBSTThe drug maker settled a patent dispute with Teva Pharmaceutical Industries over its Cubicin antibiotic. The agreement delays TEVA's production of the drug as a generic by six months and will make it easier for Cubist to market the drug, its only product. CBST is up 15 percent in the premarket.

SemiLEDs Reports Surprise Loss

The maker of light-emitting diodes reported a loss of $0.03, missing the $0.08 profit forecast. Revenue and guidance also missed the mark, and LEDS is down 23 percent before the bell.

Questcor Sees Revenue Ahead of Consensus

The pharmaceuticals company said paid prescriptions for its Acthar Gel to treat multiple sclerosis more than doubled. The company estimated it had first-quarter sale of $48.6 million, while analysts had expected $33.60 million. QCOR climbs 14 percent before the bell.

(Chart courtesy of tradeMONSTER)
Share this article with your friends



The fastest money in the market
View full report »

Premium Services

Education & Strategy

The art of trading

As I stated in last week's article, a break out or a break down needs to have a couple things happen before it is considered a confirmed break out or break down. The only problem is that in today's market where things move much more quicker than they did just a few years ago, two days could wind up being the majority of the expected movement, if not the whole movement.

View more education articles »